In 2019, 2.0 and 3.6 percent of deaths in children aged 0 to 60 months and 28 days to 6 months, respectively, attributable to RSV infection<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, May 23, 2022 (HealthDay News) — Respiratory syncytial virus (RSV) infection contributes to substantial morbidity and mortality worldwide in children aged 0 to 60 months, according to a study published online May 19 in The Lancet<\/em>.<\/p>\n You Li, Ph.D., from Nanjing Medical University in China, and colleagues conducted a systematic analysis to update RSV-associated acute lower respiratory infection morbidity and mortality among children aged 0 to 60 months for 2019. Overall, 113 new eligible studies and unpublished data from 51 studies were added to the 317 studies included in the previous review.<\/p>\n The researchers estimated that in children aged 0 to 60 months, globally in 2019, there were 33.0 million RSV-associated acute lower respiratory infection episodes, 3.6 million RSV-associated acute lower respiratory infection hospital admissions, 26,300 RSV-associated acute lower respiratory infection in-hospital deaths, and 101,400 RSV-attributable overall deaths. An estimated 6.6 million RSV-associated acute lower respiratory infection episodes, 1.4 million RSV-associated acute lower respiratory infection hospital admissions, 13,300 RSV-associated acute lower respiratory infection in-hospital deaths, and 45,700 RSV-attributable overall deaths were estimated in infants aged 0 to 6 months. Overall, 2.0 and 3.6 percent of deaths in children aged 0 to 60 months and aged 28 days to 6 months, respectively, were attributable to RSV. Across all age bands, more than 95 percent of RSV-associated acute lower respiratory infection episodes and more than 97 percent of RSV-attributable deaths were in low-income and middle-income countries.<\/p>\n “Our estimates could serve as a reference for understanding RSV epidemiology in the context of the ongoing COVID-19 pandemic,” the authors write.<\/p>\n Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n